Perioperative therapy for locally advanced gastroesophageal cancer: Current controversies and consensus of care

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Sehdev, Amikar ^a   Catenacci, Daniel Vt ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Chemoradiotherapy; Chemotherapy; Esophageal adenocarcinoma; Esophagogastric (gastroesophageal) junction cancer; Gastric adenocarcinoma; Multi disciplinary care; Stomach cancer

Indexed keywords

ACASOGZ 4051; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; RTOG 0436; RTOG 1010; TRASTUZUMAB; UFT; UNCLASSIFIED DRUG; VINBLASTINE;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CONSENSUS; CONTINUOUS INFUSION; DECREASED APPETITE; ESOPHAGUS CANCER; GASTRECTOMY; GASTROESOPHAGEAL CANCER; HEALTH CARE QUALITY; HISTOPATHOLOGY; HUMAN; INDUCTION CHEMOTHERAPY; LONG TERM SURVIVAL; LOWER ESOPHAGUS SPHINCTER; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOGENE; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SALVAGE THERAPY; STOMACH CANCER; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; CONSENSUS; HUMANS; NEOADJUVANT THERAPY; STOMACH NEOPLASMS;

EID: 84883510722     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-66     Document Type: Review

References (78)

1. Gastroesophageal cancer: focus on epidemiology, classification and staging. Sehdev A, Catenacci DVT, Discov Med 2013 16 87 103 111 23998446
2. Endotherapy for Barrett's esophagus. Konda VJ, Waxman I, Am J Gastroenterol 2012 107 827 833 10.1038/ajg.2012.70 22488078
3. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP, Lancet Oncol 2011 12 296 305 10.1016/S1470-2045(10)70125-X 21109491
4. Preinvasive neoplasia in the stomach: diagnosis and treatment. Noffsinger A, Waxman I, Clin Gastroenterol Hepatol 2007 5 1018 1023 10.1016/j.cgh.2007.07. 004 17825769
5. Transhiatal versus transthoracic esophagectomy for esophageal cancer. Barreto JC, Posner MC, World J Gastroenterol 2010 16 3804 3810 10.3748/wjg.v16.i30.3804 20698043
6. Posner MC, et al. Cancer of the Upper Gastrointestinal Tract Ontario, Canada: B.C. Decker, Inc, Posner M, Vokes EE, Weichselbaum RR, 1 2002
7. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Feith M, Stein HJ, Siewert JR, Surg Oncol Clin N Am 2006 15 751 764 10.1016/j.soc.2006.07.015 17030271 (Pubitemid 44499032)
8. A meta-analysis of D1 versus D2 lymph node dissection. Seevaratnam R, Bocicariu A, Cardoso R, Mahar A, Kiss A, Helyer L, Law C, Coburn N, Gastric Cancer 2012 15 Suppl 1 60 S69 22138927
9. Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait? Roggin KK, Hemmerich J, Posner MC, Lancet Oncol 2010 11 404 405 10.1016/S1470-2045(10)70098-X 20409753
10. Gastric cancer: Nagoya is not New York. Macdonald JS, J Clin Oncol 2011 29 4348 4350 10.1200/JCO.2011.37.5691 22010021
11. Gastric cancer-an enigmatic and heterogeneous disease. Shah MA, Ajani JA, JAMA 2010 303 1753 1754 10.1001/jama.2010.553 20442394
12. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP, N Engl J Med 1996 335 462 467 10.1056/NEJM199608153350702 8672151 (Pubitemid 26269945)
13. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, et al. Lancet Oncol 2005 6 659 668 10.1016/S1470- 2045(05)70288-6 16129366 (Pubitemid 41222756)
14. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R, J Clin Oncol 2008 26 1086 1092 10.1200/JCO.2007.12.9593 18309943
15. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M, J Clin Oncol 2001 19 305 313 11208820 (Pubitemid 32112841)
16. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, Lancet Oncol 2007 8 226 234 10.1016/S1470-2045(07) 70039-6 17329193 (Pubitemid 46291702)
17. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V, Australasian Gastro-Intestinal Trials G, Lancet Oncol 2011 12 681 692 10.1016/S1470-2045(11)70142-5 21684205
18. Preoperative chemoradiotherapy for esophageal or junctional cancer. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al. N Engl J Med 2012 366 2074 2084 10.1056/NEJMoa1112088 22646630
19. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA, N Engl J Med 2001 345 725 730 10.1056/NEJMoa010187 11547741
20. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, et al. J Clin Oncol 2012 30 2327 2333 10.1200/JCO.2011.36.7136 22585691
21. Adjuvant therapy for gastric cancer: revisiting the past to clarify the future. Brooks GA, Enzinger PC, Fuchs CS, J Clin Oncol 2012 30 2297 2299 10.1200/JCO.2012.42.4069 22585690
22. Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008)[Abstract]. Macdonald JS, Benedetti J, Smalley S, Haller D, Hundahl S, Jessup J, Ajani J, Gunderson L, Goldman B, Martenson J, J Clin Oncol 2009 27 15s suppl; abstr 4515 10.1200/JCO.2008.21.7695
23. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, et al. Int J Radiat Oncol Biol Phys 2005 63 1279 1285 10.1016/j.ijrobp.2005.05.005 16099596 (Pubitemid 41628018)
24. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Kim TH, Park SR, Ryu KW, Kim YW, Bae JM, Lee JH, Choi IJ, Kim YJ, Kim DY, Int J Radiat Oncol Biol Phys 2012 84 585 e592 10.1016/j.ijrobp.2012. 07.2378 22975616
25. Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center. Costa WL Jr, Coimbra FJ, Fogaroli RC, Ribeiro HS, Diniz AL, Begnami MD, Mello CA, Fanelli MF, Silva MJ, Fregnani JH, Montagnini AL, Radiat Oncol 2012 7 169 10.1186/1748-717X-7-169 23068190
26. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. Lee J, Lim Do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, et al. J Clin Oncol 2012 30 268 273 10.1200/JCO.2011.39.1953 22184384
27. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Group MRCOCW, Lancet 2002 359 1727 1733 12049861
28. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, et al. J Clin Oncol 2010 28 5210 5218 10.1200/JCO.2009.26.6114 21060024
29. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE, J Clin Oncol 2009 27 5062 5067 10.1200/JCO.2009.22. 2083 19770374
30. Alderson D, A Randomised Controlled Trial Comparing Standard Chemotherapy Followed By Resection Versus Ecx Chemotherapy Followed By Resection In Patients With Resectable Adenocarcinoma Of The Oesophagus UK Clinical Research Network Study Portfolio 2005 http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID= 854
31. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, et al. N Engl J Med 2007 357 1810 1820 10.1056/NEJMoa072252 17978289 (Pubitemid 350044801)
32. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y, J Clin Oncol 2011 29 4387 4393 10.1200/JCO.2011.36.5908 22010012
33. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, et al. JAMA 2010 303 1729 1737 20442389
34. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, et al. Lancet 2012 379 315 321 10.1016/S0140-6736(11)61873-4 22226517
35. Kang WK, Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma: The ARTIST II Trial (ARTIST-II) US National Library of Medicine 2013 ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/study/ NCT01761461?term=artist+II&rank=1
36. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, et al. N Engl J Med 1998 339 1979 1984 10.1056/NEJM199812313392704 9869669 (Pubitemid 29024130)
37. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG, J Clin Oncol 2007 25 3719 3725 10.1200/JCO.2006.10.4760 17704421 (Pubitemid 47372613)
38. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. N Engl J Med 2006 355 11 20 10.1056/NEJMoa055531 16822992
39. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, et al. J Clin Oncol 2011 29 1715 1721 10.1200/JCO.2010.33.0597 21444866
40. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, Roth A, Schuller JC, Fiori G, Orsi F, et al. World J Gastroenterol 2010 16 868 874 20143466
41. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ferri LE, Ades S, Alcindor T, Chasen M, Marcus V, Hickeson M, Artho G, Thirlwell MP, Ann Oncol 2012 23 1512 1517 10.1093/annonc/mdr465 22039085
42. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Homann N, Pauligk C, Luley K, Werner Kraus T, Bruch HP, Atmaca A, Noack F, Altmannsberger HM, Jager E, Al-Batran SE, Int J Cancer 2012 130 1706 1713 10.1002/ijc.26180 21618509
43. Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer [Abstract]. Bajetta E, Floriani I, Bartolomeo MD, Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial, J Clin Oncol 2012 30 suppl; abstr LBA4001
44. Adjuvant paclitaxel followed by oral fluoropyrimidines for gastric cancer: Safety data of the factorial phase III SAMIT trial [Abstract]. Kobayashi M, Tsuburaya A, Yoshida K, Yoshino S, Miyashita Y, J Clin Oncol 2012 30 suppl 4; abstr 72
45. SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer [Abstract]. Yoshida K, Tsuburaya A, Kobayashi M, Yoshino S, Takahashi M, Takiguchi M, Tanabe K, Takahashi N, J Clin Oncol 2013 31 suppl; abstr LBA4002
46. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101 [Abstract]. Fuchs CS, Tepper JE, Niedzwiecki D, Hollis D, Mamon HJ, Swanson R, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Enzinger PC, Goldberg RM, Venook AP, Mayer RJ, J Clin Oncol 2011 29 suppl; abstr 4003
47. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Sarkaria IS, Rizk NP, Bains MS, Tang LH, Ilson DH, Minsky BI, Rusch VW, Ann Surg 2009 249 764 767 10.1097/SLA.0b013e3181a38e9e 19387328
48. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U, J Clin Oncol 2001 19 3058 3065 11408502 (Pubitemid 32565444)
49. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR, J Clin Oncol 2006 24 4692 4698 10.1200/JCO.2006.06.7801 16966684 (Pubitemid 46646244)
50. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, et al. Lancet Oncol 2007 8 797 805 10.1016/S1470- 2045(07)70244-9 17693134 (Pubitemid 47308659)
51. The value of PET imaging in patients with localized gastroesophageal cancer. Ott K, Herrmann K, Krause BJ, Lordick F, Gastrointest Cancer Res 2008 2 287 294 19259277
52. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. zum Buschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H, et al. J Nucl Med 2011 52 1189 1196 10.2967/jnumed.110.085803 21764790
53. Lorenzen S, Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG) (HICON) US National Library of Medicine 2010 ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/NCT01271322
54. Goodman KA, Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer US National Library of Medicine 2011 ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/NCT01333033? term=calgb+80803&rank=1
55. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg imaging program in cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J, et al. BMC Cancer 2011 11 266 10.1186/1471-2407-11-266 21702914
56. Preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in locally advanced gastroesophageal junction and gastric adenocarcinoma. Ku GY KD, Strong VE, Schöder H, Janjigian YY, Shah MA, Coit DG, Brennan MF, Capanu M, Ilson DH, J Clin Oncol 2013 31 suppl bstr 4101
57. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A, et al. J Clin Oncol 2009 27 851 856 10.1200/JCO.2008.17.0506 19139439
58. Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 [Abstract]. Alberts SR, Soori GS, Shi Q, Wigle DA, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Wu TT, Yoon HH, Drevyanko TF, Ko S, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP, J Clin Oncol 2013 31 suppl; abstr 4026
59. Treatment of thoracic esophageal carcinoma invading adjacent structures. Seto Y, Chin K, Gomi K, Kozuka T, Fukuda T, Yamada K, Matsubara T, Tokunaga M, Kato Y, Yafune A, Yamaguchi T, Cancer Sci 2007 98 937 942 10.1111/j.1349-7006. 2007.00479.x 17441965 (Pubitemid 46865374)
60. Reynolds JV, Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (MAGIC Regimen) vs. Neoadjuvant Chemoradiation (CROSS Protocol) in Adenocarcinoma of the Oesophagus and Oesophago-gastric Junction US National Library of Medicine 2012 ClinicalTrials.gov [online]. http://clinicaltrials.gov/ show/NCT01726452
61. Verheji M, A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study) March 31, 2013. http://clinicaltrials.gov/ct2/show/NCT00407186?term=NCT00407186&rank=1
62. Leong T, A Randomised Phase II/III Trial of Preoperative Chemoradiotherapy Versus Preoperative Chemotherapy For Resectable Gastric Cancer. Australian Cancer Trials 2009 http://www.australiancancertrials.gov.au/ search-clinical-trials/search
63. SCOPE 1: a phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab. Crosby THC, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bridgewater JA, Geh I, Cunningham D, Maughan T, Griffiths G, J Clin Oncol 2012 30 suppl 34 bstr LBA3
64. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, Phillips CJ, Blazeby JM, Crosby TD, BMC Cancer 2011 11 466 10.1186/1471-2407-11-466 22035459
65. Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Power DG, Ilson DH, Ther Adv Med Oncol 2009 1 145 165 10.1177/1758834009347323 21789119
66. Trastuzumab for gastric cancer. Meza-Junco J, Au HJ, Sawyer MB, Expert Opin Biol Ther 2009 9 1543 1551 10.1517/14712590903439702 19916733
67. Safran H, A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma US National Library of Medicine 2010 ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/NCT01196390?term=RTOG1010&rank=1
68. Reed CE, A Phase II Study of Neoadjuvant Therapy With Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients With Locally Advanced Adenocarcinoma of the Distal Esophagus US National Library of Medicine 2008 ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/ show/NCT00757172?term=acosog +z4051&rank=1
69. Ilson D, A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery US National Library of Medicine 2008 ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/NCT00655876?term= NCT00655876&rank=1
70. Erbitux Add-On Falls Short in Esophageal Ca [Abstract]. Crosby T, Hurt C, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bridgewater JA, Geh I, Cunningham D, Maughan T, Griffiths G, J Clin Oncol 2012 30 suppl 34; abstr LBA3
71. Saba N, Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer US National Library of Medicine 2011 ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/NCT01490749? term=NCT01490749&rank=1
72. Chen L, Phase III, Randomized, Multicenter, Controlled Evaluation of S1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients US National Library of Medicine 2012 ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/NCT01583361?term=NCT01583361&rank=1 23980090
73. Shen L, A Randomized, Multicenter, Controlled Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection US National Library of Medicine 2012 ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/ NCT01534546?term=NCT01534546&rank=1
74. Nordwest K, A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach US National Library of Medicine 2010 ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/NCT01216644? term=NCT01216644&rank=1
75. Cunningham D, A Randomized Controlled Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma US National Library of Medicine 2007 ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/NCT00450203? term=NCT00450203&rank=1
76. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY, et al. Ann Oncol 2013 24 1754 1761 10.1093/annonc/mdt106 23524864
77. Towards personalized treatment for gastroesophageal adenocarinoma: Strategies to address inter- and intra- patient tumor heterogeneity: PANGEA. Catenacci DVT, Polite B, Henderson L, Xu P, Carey GB, Liao WL, Hembrough T, Burrows J, Karrison T, Hart J, Xiao SY, Fitzpatrick C, Marsh R, Vokes E, Olopade O, Villaflor V, Salgia R, Kindler H, Schilsky R, [ http://www.winsymposium.org/ previous-symposia/win-2013/program-at-a-glance/presentations-july-12/ ]
78. Molecular profiling of cancer-the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Stricker T, Catenacci DV, Seiwert TY, Semin Oncol 2011 38 173 185 10.1053/j.seminoncol.2011.01.013 21421108